2965 KB17 KB199220251993Biro, J...Cserhalmi, J... P.Horvath, A...Jakob, E...Marschalko, M...Papp, I...letnik:2številka:3str. 87-90ISSN:1318-4458COBISSID_HOST:2639321URN:URN:NBN:SI:doc-X1P22C2OenSlovene Welding SocietyActa dermatovenerologica Alpina, Pannonica et AdriaticaAdrenal cortex hormonesAdverse effectsCyclosporinsDermatomyositisDrug therapyEtiologyKidney diseasesTherapeutic useCyclosporin for the treatment of dermatomyositis|2 patients with extreme severe dermatomyositis, 2 patients who were at risk because of corticosteroid side effects due to underlying diseases-and 1 patient with amyopathic dermatomyosistis who resistant to previous corticosteroid treatment were treated with 5mg/kg/d cyclosporin A (CSP) and prednisone. CSP treatment has been shown to be beneficial in all 5 patients. CSP treatment was discontinued after 3 and 4 months in 2 of the patients with severe disease course because of renal side effects, which were veresible. In no cases were found underlying malignancies. CSP treatment seems to be a valuable second line drug in extreme severe cases of dermatomyositis, in cases who are at risk because of corticosteroid side effects, and in patients who are unresponsive to corticosteroid treatmentTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaZdruženje slovenskih dermatovenerologov